Famciclovir
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Recurrent Genital Herpes (RGH)
Conditions
Recurrent Genital Herpes (RGH)
Trial Timeline
Jun 1, 2003 → Jun 1, 2005
NCT ID
NCT00219310About Famciclovir
Famciclovir is a approved stage product being developed by Novartis for Recurrent Genital Herpes (RGH). The current trial status is completed. This product is registered under clinical trial identifier NCT00219310. Target conditions include Recurrent Genital Herpes (RGH).
What happened to similar drugs?
3 of 20 similar drugs in Recurrent Genital Herpes (RGH) were approved
Approved (3) Terminated (0) Active (17)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00878072 | Phase 2/3 | Completed |
| NCT00448227 | Phase 2 | Completed |
| NCT00098046 | Phase 3 | Completed |
| NCT00098059 | Phase 3 | Completed |
| NCT00129818 | Approved | Completed |
| NCT00248144 | Approved | Completed |
| NCT00219310 | Approved | Completed |
| NCT00171990 | Phase 3 | Completed |
Competing Products
20 competing products in Recurrent Genital Herpes (RGH)